Gene expression profiling has implicated several intracellular signalling cascades, including the JAK/STAT pathway, in the pathogenesis of particular subtypes of lymphoma. In marked contrast to the situation in patients with either acute lymphoblastic leukaemia or a myeloproliferative neoplasm, JAK2 coding sequence mutations are rare in lymphoma patients with an activated JAK/STAT "signature". This is instead the consequence of mutational events that result in the increased expression of non-mutated JAK2; positively or negatively affect the activity of other components of the JAK/STAT pathway; or establish an autocrine signalling loop that drives JAK-mediated cytokine-independent proliferation. Here, we detail these genetic lesions, their functional consequences, and impact on patient outcome. In light of the approval of a JAK1/JAK2 inhibitor for the treatment of myelofibrosis, and preliminary studies evaluating the efficacy of other JAK inhibitors, the therapeutic potential of compounds that target JAK/STAT signalling in the treatment of patients with lymphoma is also discussed.
Introduction
The lymphomas are lymphoid malignancies that arise after the transformation of maturing Bor T-lymphocytes. There are over 30 distinct clinical entities that fall within this disease classification, with the most frequently occurring being follicular lymphoma (FL), diffuse large B-cell lymphoma (DLBCL) and Hodgkin's lymphoma (HL). It is estimated that, in 2011 in the United States alone, more than 700,000 people were living with lymphoma and another 80,000 individuals being diagnosed each year (Surveillance, Epidemiology, and End Results (SEER) Program; http://seer.cancer.gov/statfacts/). The diversity of diseases categorised as a lymphoma reflects both the developmental stage of the transformed lymphocyte, and the molecular events that underlie its transformation. In the last several years, use of next-generation sequencing technologies to interrogate the genome and transcriptome of various lymphoma subtypes has provided significant insights into their molecular aetiology. Amongst the recurrent somatic lesions identified in this manner are NOTCH2 truncating mutations, which occur in patients with splenic marginal zone lymphoma 1, 2 ; missense ID3 mutations in those with Burkitt's lymphoma (BL) 3 ; inactivating CREBBP mutations in cases of follicular lymphoma (FL) or diffuse large B-cell lymphoma (DLBCL) 4 ; loss-of-function mutations in MLL2 in DLBCL
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ACCEPTED MANUSCRIPT 5 1 and JAK-homology-2 (JH1 and JH2) domains. However, JH2 domains lack several features traditionally considered important for a functioning kinase. Nonetheless, the JH2 domain of JAK2 has an essential role in suppressing basal kinase activity, 8, 9 which might explain why it is the predominant target for acquired activating mutations associated with a hematologic malignancy. In a cytokine-free environment, this domain is constitutively phosphorylated on serine-523 and tyrosine-570, which strengthens inhibitory interactions between it and the JH1domain, thereby suppressing the kinase activity of the JH1 domain. 10, 11 Engagement of a receptor with its cognate ligand induces structural changes within the receptor, 12 facilitating JAK2 auto-phosphorylation on tyrosine residues Y1007 and Y1008, with a concomitant decrease in the levels of phosphorylated serine-523 and tyrosine-570. Upon activation, the JAK proteins phosphorylate tyrosine residues within the cytoplasmic domain of the receptors to which they are bound, thereby providing docking sites for various signalling proteins, such as members of the signal-transducer-and-activator-of-transcription transcription factor family (STATs 1, 2, 3, 4, 5A, 5B and 6). Recruited STAT monomers become activated by JAKmediated phosphorylation, dimerise and translocate into the nucleus, where they enhance transcription at specific loci. Activated JAKs also induce the activation of other downstream signalling cascades, including the MAP kinase and PI-3-kinase/AKT pathways.
It has long been appreciated that the JAK proteins are not exclusively cytoplasmic, but little was known about their nuclear activity. In 2006, studies of modifiers of JAK activity in Drosophila identified a non-canonical JAK signalling pathway in which activated Hopscotch (Hop), the single JAK protein in flies, disrupts gene silencing by displacing heterochromatin protein-1 (Hp1), which in turn induces the aberrant expression of normally silenced genes. 13 Deregulated expression of several of these genes led to the development of a leukaemia-like phenotype in flies that carry an activating Hop mutation. Nuclear JAK2 is also present in mammalian hematopoietic cell-lines and primary CD34 + progenitors, but not
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6 in mature blood cells. 14, 15 There, JAK2 directly phosphorylates histone H3 on tyrosine-41 (H3Y41), which excludes the chromo-shadow domain of the heterochromatin protein, HP1, from binding to this site. HP1 displacement leads to alterations in the chromatin structure that surrounds transcriptionally inactive genes. 15, 16 Accordingly, phosphorylated H3Y41 is localized to a subset of active genomic promoters, and present throughout the coding region of functionally important genes such as GATA2 and TAL1. 17 Phospho-H3Y41 is also present at cis regulatory elements to which STAT5 is bound, demonstrating that the transcription of some loci is regulated by both the canonical and non-canonical JAK signalling pathways.
Histone phosphorylation is not the only effect that JAK2 has on chromatin structure. It also interacts with PMRT5, an arginine methyltransferase that mediates the di-methylation of arginine residues within the H2A, H3 and H4 histones. 18, 19 JAK2-mediated phosphorylation of PMRT5 significantly reduces its methyltransferase activity, changing the pattern of histone modification within the cell, and altering gene expression patterns. 19 JAK2 has also recently been shown to phosphorylate EZH2, 20 a methyltransferase that is the catalytic subunit of the polycomb repressive complex 2 (PRC2). Unmodified EZH2 inhibits gene transcription by methylating histone H3 on lysine-27 (H3K27) 21, 22 ; phosphorylation targets it for proteosomal degradation, thereby alleviating this transcriptional repression.
As discussed in a later section of this review, genomic amplification that results in the over-expression of non-mutated JAK2 in some lymphoma sub-types has an impact on both canonical and non-canonical JAK signalling pathways in mutation-positive cells.
JAK3, but not JAK2, point mutations are associated with lymphomagenesis
Given that a significant proportion of patients with lymphoma display abnormal JAK/STAT activation, it is reasonable to question whether this may be the result of mutations that affect one or more members of the JAK family members. Mutations in JAK1 and TYK2 have not
been observed in lymphoma patients, although JAK2 and JAK3 mutations have been detected in a proportion of cases. Somatic JAK2 mutations occur frequently in some hematologic malignancies, particularly those affecting the myeloid lineages. An acquired activating mutation, JAK2V617F, is present in the majority of patients diagnosed with a myeloproliferative neoplasm (MPN), whereas JAK2 "exon 12" mutations are acquired by a subset of patients that lack the JAK2V617F mutation ( Figure 1A ). [23] [24] [25] [26] [27] However, JAK mutations are not only associated with the transformation of myeloid cells; a third type of JAK2 activating mutation, which affects arginine-683 or adjacent residues, is present in 20%
of patients with Down syndrome-associated or high-risk sporadic acute lymphoblastic leukaemia (ALL). [28] [29] [30] In contrast, JAK2 mutations occur rarely in patients with lymphoma, [31] [32] [33] although ~1% of patients with classical HL (cHL) carry a reciprocal t(4;9)(q21;p24)
translocation that generates a chimeric protein consisting of the proximal end of SEC31A, a protein involved in vesicular transport, fused to the distal half of JAK2 ( Figure 1A ). 34 The expression of SEC31A/JAK2 enables cytokine-independent proliferation in vitro, and the emergence of an aggressive T-lymphoblastic lymphoma in vivo. arising in young patients and involving the mediastinum at presentation; an entity termed mediastinal gray zone lymphoma (MGZL) has been identified that has features of PBML and HL, but cannot readily be assigned to either category. 44 There is also evidence of a disease continuum between the two disorders, with occasional patients initially diagnosed with cHL developing PBML shortly after treatment. Analysis of matched HL and PMBL samples from three such individuals revealed the presence of common genomic lesions, implying that these disease states were directly related rather than arising separately. 45 HL and PMBL share a common set of genetic mutations, the most well-characterized of which is a focal amplification of chromosome 9p24, which occurs in approximately 55% of patients with PMBL, 35% of those with HL, and 50% of those with MGZL. [45] [46] [47] [48] [49] [50] Comparative genomic hybridization revealed that the common amplified region spanned 3.5Mb and involved 21 genes, ten of which were over-expressed in affected hematopoietic cells. sequence similarity to importin-5 suggests that it may be involved in nuclear transport.
JMJDC2 is a Fe-and 2-oxyglutarate-dependent dioxygenase that catalyzes the demethylation of histone H3 lysine-9 (H3K9). 52 Given the role that JAK2 plays in modifying the epigenome, Rui and colleagues evaluated the possibility that these two proteins synergize to relax regions of the genome with a condensed chromatin structure, thereby altering gene expression patterns. shRNA-mediated JMJDC knockdown sensitized amplicon-positive lymphoma cell-lines to JAK2 pharmacologic inhibition, confirming that JMJDC2 and JAK2
co-operate to ensure the survival and expansion of these cells. 51 This dual treatment scheme also increased the number of nuclear foci containing high levels of HP1, demonstrating that JMJDC2 and JAK2 co-operatively suppress heterochromatin formation.
51
JAK2 and JMJDC2 modify histone H3, with JAK2 phosphorylating residue tyrosine-41
and JMDJDC2 demethylating tri-methylated lysine-9 and lysine-36 (me3K9 and me3K36).
HP1 binds to these three residues through its chromo-shadow and chromo domains; their modification inhibits these interactions ( Figure 2 ). Genome-wide analysis of the distribution of phosphorylated H3Y41 in amplicon-positive lymphoma cells showed that the co-operation
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11 between JAK2 and JMJDC2 alters the transcription pattern of numerous loci, including the MYC and IL4RA genes, as well as those encoding JAK2 and JMJDC2 themselves. 51 Increased synthesis of IL4RA, JAK2 and JMJDC2 therefore sets up two positive feedback loops, which enhance autocrine IL13/JAK/STAT-mediated signalling ( Figure 2 ).
Inactivating SOCS mutations enhance JAK activation in lymphoma cells
A proportion of PMBL and HL tumours are not positive for the 9p24 amplicon, yet they are characterized by the activation of JAK/STAT signalling, 40, 41 suggesting that, in at least some instances, patients have acquired other mutations that deregulate this pathway. Indeed, some lymphomas carry an acquired mutation in SOCS1, [53] [54] [55] 53-55 They also occur in a quarter of FL or DLBCL cases, and at lower frequencies in cases of
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12 mutations are predominantly mono-allelic, whereas most affected lymphoid cell-lines contain bi-allelic SOCS1 mutations. About half of these mutations result in protein truncation by causing a frame-shift that often adds a variable number of additional (nonsense) amino acids ( Figure 3A) . In other instances, mutations do not perturb the reading frame, but instead result in an interstitial deletion. These can occur throughout the protein but are concentrated around the SH2 domain and SOCS box, and are predicted to interfere with its ability to bind to phosphorylated JAKs or form a functional E3 ligase complex. In support of either possibility, immunohistochemical analysis of bone marrow samples from those patients with cHL and a SOCS1 mutation showed high levels of phosphorylated STAT5. 53 Elevated levels of phospho-STAT6 are similarly associated with the presence of a SOCS1 mutation in patients with NLPHL. 55 In addition, JAK2 turnover is significantly impaired in the MedB-1 cell-line, which is derived from a patient with PMBL and carries two mutant SOCS1 alleles. 56 Ectopic expression of wild-type SOCS1 in these cells substantially reduced their proliferation rate, with a concomitant decrease in the levels of phosphorylated and total JAK2 and STAT5.
The genetic lesions that increase JAK2 copy number or inactivate SOCS1 do not occur in mutually exclusive subsets of patients. In an analysis of 17 PMBL samples, nine were positive for a SOCS1 mutation, and eight had a wild-type genotype; in both subgroups, the majority was also positive for the 9p24 amplicon (seven and six samples, respectively).
55
Rather than providing an alternate mechanism for enhanced JAK/STAT signalling in patients that lack the 9p24 amplicon, SOCS1 mutations may act primarily to boost JAK2 activity even further. A similar situation occurs in acute lymphoblastic leukaemia (ALL), where patients that are positive for an acquired JAK2 mutation often also carry an activating mutation in CRLF2, which is part of the receptor for thymic stromal lymphopoietin, and which signals through JAK2.
57, 58
A C C E P T E D M A N U S C R I P T ; these included missense, nonsense and frame-shift mutations, as well as single-residue deletions ( Figure 3B ). In numerous cases, co-existent PTPN1 and SOCS1 mutations were detected. Immunohistochemical assessment of tissues from patients with cHL or PMBL revealed that PTPN1 protein levels were reduced in mutation-positive cases. Furthermore, in vitro analyses revealed that all PTPN1 mutants had reduced phosphatase activity compared to wild-type PTPN1, 59 with the impairment level dependent upon the specific mutation present. For example, the Q9 and R156 frame-shift mutants had <10% wild-type PTPN1 activity, whereas the V182D and M282L substitutions had about 30% and 80% activity, respectively. As a consequence of the reduced phosphatase activity, phospho-STAT6 levels induced by exposure of these cells to IL4 remain elevated.
Similarly, increased levels of phosphorylated JAK1, JAK2, STAT3, STAT5 and STAT6
were observed in a HL cell-line in which PTPN1 levels were reduced by shRNA-mediated knockdown.
Bi-allelic mutations in PTPN2 can also occasionally occur in patients with HL or T-cell non-Hodgkin's lymphoma (NHL) 60 ( Figure 3C ). In almost all cases identified, one entire PTPN2 allele was deleted, whilst the other allele encoded nonsense mutations resulting in severe protein truncation, or amino acid substitutions that are predicted to disrupt an -helix in the protein tyrosine phosphatase domain. In a single patient, both PTPN2 alleles carried a frame-shift mutation within exon 2; each is predicted to encode a significantly truncated polypeptide (E41fs and R45fs). Introduction of wild-type or mutant PTPN2 into BaF3 cells
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14 revealed that mutant PTPN2 is expressed at substantially lower levels than its wild-type counterpart. 60 However, as might be anticipated, expression of mutant PTPN2 resulted in increased levels of phospho-JAK1, with concomitant increases in levels of phospho-STAT1
and phospho-STAT3, but not phospho-STAT6.
These data collectively suggest that inappropriate activation of JAK/STAT signalling in subsets of patients with lymphoma may result from, or be enhanced by, inactivating PTPN1 or PTPN2 mutations.
Lymphoma patients may also have acquired mutations affecting a STAT family member.
Although mutations that target the STAT proteins occur rarely in hematologic malignancies, several studies have recently identified lymphoma patients with an acquired STAT3 mutation, including four of 126 patients with NHL (all of whom had DLBCL) and five of 55 patients with DLBCL. 5, 61 Couronne and colleagues also reported STAT3 mutations in two of 79 DLBCL cases, two of 45 patients with a T-cell lymphoma, and two of ten patients with an anaplastic large cell lymphoma. 62 The affected residues in many instances map to the SH2 domain, although an activating substitution in the coiled-coil domain was reported 63 ( Figure   3D ). In vitro expression of these variants resulted in increased phosphorylation, nuclear translocation, and transcriptional activity of STAT3. [62] [63] [64] An abnormal blood phenotype was apparent in mice transplanted with bone marrow cells expressing the Y640F mutant, although this was myeloproliferative in nature rather than lymphoproliferative. 62 Ritz and colleagues also identified recurrent heterozygous STAT6 mutations in 36% of patients with PMBL. 65 Each mutation caused an amino acid substitution in the STAT6 DNA binding domain ( Figure 3C ), primarily affecting residues N417 or D419. These mutations
were not restricted to patients lacking the 9p24 amplicon: of the 47 patient samples that were analysed for JAK2, SOCS1 and STAT6 mutations, 20 had mutations affecting one of these A C C E P T E D M A N U S C R I P T genes, whereas 17 had mutations affecting two, and five had mutations affecting all three.
Presence of nuclear phospho-STAT6 in patients with a STAT6 mutation suggested that these may be activating mutations, although nuclear phospho-STAT6 was also observed in most patients that lacked a STAT6 mutation. Surprisingly, in vitro studies suggested that the DNA binding activity of mutated STAT6 was impaired rather than enhanced 65 ; consistent with this finding, crystallographic studies identified the N417 and D419 residues as being located in a DNA recognition element within the STAT polypeptides. 66, 67 Recently, approximately 10%
of cases of FL were also found to carry an acquired STAT6 mutation. 
MYD88 mutations affect JAK/STAT signalling in a subset of patients with ABC DLBCL
Gene expression profiling reveals that the NF-B signalling pathway is constitutively active in patients with the ABC subtype of DLBCL. This may be as a consequence of a CARD11 mutation (in ~10% of cases) 70 , an inactivating TNFAIP3 mutation (in almost 25% of cases) 71 , or constitutively active B-cell receptor signalling arising from CD79A or CD79B mutations (in more than 20% of cases). 72 However, some patients also have constitutive activation of the JAK/STAT pathway, such that STAT3-mediated signalling synergizes with NF-B to promote cell survival. The molecular basis of this phenomenon was elucidated in an RNA
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16 interference screen for genes essential for the proliferation or survival of ABC DLBCL celllines. 73 This study identified three independent shRNAs that target MYD88, a signalling adaptor protein that activates the NF- pathway in response to stimulation of the toll-like receptors and the IL1 and IL8 receptors (Figure 4) . Whole transcriptome sequence analysis of ABC DLBCL cell-lines revealed the presence of a single L265P substitution within MYD88;
this variant was also detected in 29% of ABC DLBCL biopsies, with slightly more than half
showing an additional gain of copy number at the mutant MYD88 locus, suggesting that this mutation may provide lymphoma cells with a dose-dependent competitive advantage. The L265P mutation occurred rarely in the GCB or PMBL subtypes, but was present in 10% of patients with gastric mucosa-associated lymphoid tissue (MALT) lymphomas and >90% of patients with Waldenstrom's macroglobulinaemia, an IgM-secreting lymphoplasmacytic lymphoma. 74 Other MYD88 variants were detected in ~10% of DLBCL biopsies (both ABC and GCB subtypes); these were mostly located within its TIR domain, which interacts with various growth factor receptors.
In vitro experiments revealed that the L265P substitution is a gain-of-function mutation to which mutation-positive ABC DLBCL cell-lines are addicted. 73 In the absence of signalling through a toll-like receptor or the receptors for IL1 or IL8, mutant MYD88, but not its wild-type counterpart, spontaneously associates with the IRAK1 and IRAK4 kinases, resulting in the phosphorylation of IRAK1 by IRAK4. shRNA-mediated knockdown of IRAK4 levels, or inhibition of its kinase activity by a small molecule inhibitor of IRAK1/4, proved toxic to mutation-positive ABC DLBCL cell-lines. IRAK1 and IRAK4 activation by mutant MYD88 initiates a phosphorylation cascade that results in I phosphorylation, and its proteosomal degradation (Figure 4) . NF- then translocates from the cytoplasm into the nucleus, where it enhances transcription from specific loci. Use of NF- reporter constructs in a GCB cell-line engineered to express various MYD88 species suggests that the L265P,
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M232T and S243N mutants were potent inducers of NF- signalling, the S22R and T294T variants were moderate inducers, and wild-type MYD88 had minimal activity.
Expression profiling of an ABC DLBCL cell-line both before and after knockdown of mutant MYD88 revealed that, in addition to activation of NF- signalling, the JAK/STAT and type I interferon signalling pathways are activated by the L265P substitution mutant. 73 Amongst the differentially expressed transcripts within the NF- and JAK/STAT signatures were those for IL6 and IL10. This finding was striking, as autocrine secretion of either cytokine activate JAK1/2-and STAT3-mediated signalling in a significant proportion of patients with the ABC sub-type. 75 shRNA-mediated MYD88 knockdown, or exposure to an IRAK1/4 inhibitor, reduced levels of IL6 and IL10 that were secreted by mutation-positive ABC DLBCL cell-lines, and reduced levels of phospho-STAT3. 73 Acquisition of a MYD88 mutation therefore establishes an autocrine-signalling loop in which nuclear NF- enhances the synthesis of IL6 and IL10, which are secreted into the microenvironment. There, these cytokines engage their cognate receptors expressed on the surface of tumour cells, causing activation of JAK1, JAK2 and STAT3. Nuclear phospho-STAT3 then co-operates with NF- to enhance IL6 and IL10 synthesis. These cytokines are likely to influence neighbouring non-malignant immune cells, although these effects have not been investigated.
Intriguingly, individuals that carry a (-94ATTG)del polymorphism within their NFKB1
gene promoter have higher plasma levels of IL6 and IL10. 76 Those that develop DLBCL have an inferior progression free and overall survival rate, highlighting the important of the IL6 and IL10 autocrine signalling loops in DLBCL biology.
JAK/STAT inhibitors as potential new therapeutic agents for the treatment of lymphoma
As enhanced JAK-mediated signalling is observed in the malignant cells of a significant number of patients with lymphoma, particularly those diagnosed with PMBL or HL, this 
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(4) Ruxolitinib (Jakafi™) is a pyrrolo [2,3-d] pyrimidine analogue that exhibits nanomolar affinity for both JAK1 and JAK2 (with IC 50 values of 2.7nM and 4.5nM, respectively). In a multi-centre study of 153 patients with myelofibrosis, this drug was well tolerated and had beneficial effects against splenomegaly and constitutional symptoms. 83 Two randomized Phase III trials in myelofibrosis patients were subsequently reported: COMFORT-I, a placebo-controlled trial of 309 patients 84 ; and COMFORT-II, a comparison of Ruxolitinib to best available therapy in 219 patients. 85 Ruxolitinib significantly affected splenomegaly, with almost all patients experiencing a reduction in volume, and overall improvement in qualityof-life was reported in half of those receiving Ruxolitinib. The most frequent adverse events were anaemia or thrombocytopenia, which could be managed by a dose reduction or brief interruption in treatment. A Ruxolitinib-mediated reduction in circulating pro-inflammatory cytokine levels is attributed to its inhibitory effects on JAK1-mediated signalling 83 ; this may make Ruxolitinib an attractive therapeutic agent for MYD88 mutation-positive lymphoma patients, as this mutation causes cell-autonomous activation of JAK1 and JAK2 (Figure 4) .
However, the effects of Ruxolitinib on primary cHL and/or PMBL cell proliferation in vitro or in vivo have not yet been reported.
These JAK inhibitors might be used in conjunction with existing therapies, or with other agents that also inhibit JAK2 activity, such as the HSP-90 inhibitors. 86 Alternately, drugs that target particular downstream effectors of activated JAKs, such as those that inhibit STAT activity, should be considered. Although there is little published data on the efficacy of STAT inhibitors on lymphoma cells, one such agent, OPB-31121 (Otsuka Pharmaceuticals), had a strong inhibitory effect on the growth of all BL cell-lines tested (n=3) and in five of nine DLBCL cell-lines, in addition to a number of other hematologic malignancies. 87 Phase I/II studies in patients with NHL (NCT1406574) are underway.
A C C E P T E D M A N U S C R I P T
Is JAK/STAT inhibition beneficial for all lymphoma sub-types?
Given that a sizeable proportion of lymphoma patients show activation of the JAK/STAT signalling, especially those with the PMBCL and HL sub-types, it is reasonable to question whether all lymphoma sub-types might be amendable to treatment with a JAK inhibitor.
However, a recent study has suggested that JAK2 activation plays a key role in maintaining control of B-cell proliferation in the germinal centre (GC). 20 As a consequence, those lymphoma sub-types that arise following the transformation of a germinal B-cell, such as BL,
Fl and GC-DLBCL, are not predicted to benefit from the inhibition of JAK2 activity.
In but not overt B-cell transformation. 94 Treatment of patients with these lymphoma subtypes would therefore prove to not be beneficial, but may also not cause harm.
Concluding comments
Gene expression profiling and genomic sequence determinations performed over the last Mutations in MYD88 (shown here in green) cause the spontaneous formation of a complex between it and the IRAK1 and IRAK4 serine/threonine kinases. In healthy cells, this complex is assembled only after MYD88 interacts with a Toll-like receptor (TIR) or the IL1 receptor.
IRAK4 is then within close proximity to IRAK1, and is able to phosphorylate it, initiating a signalling cascade that includes the phosphorylation of TAK1, the  and  chains of I-kappa-B kinase (IKK), and I. This ensures the ubiquitinylation and proteosomal degradation of I, which serves to inhibit and maintain within the cytoplasm the NF- transcription factor. MYD88 mutation ultimately allows the nuclear translocation of NF-, which then binds to specific regulatory elements within target genes, and enhances their transcription.
Amongst the loci directly affected are those that encode IL6 and IL10, setting an autocrine- and H3K27me3 epigenetic marks (collectively indicated here by a green circle labelled "M").
As a consequence, cell cycle checkpoints are silenced and rapid B-cell proliferation occurs.
In later stages of B-cell development, EZH2 is once more silenced, permitting exit from the GC and subsequent differentiation. This process is initiated by the activation and nuclear translocation of JAK2, and by its phosphorylation of EZH2 on tyrosine-641 (Y641).
Phosphorylated EZH2 is a substrate for the -TrCP SCF E3 ubiquitin ligase complex, which initiates the polyubiquitinylation of EZH2 (indicated here as a brown circle labelled "U"), and its eventual proteosomal degradation. JAK2-mediated degradation of EZH2 is impaired in a significant proportion of GC-DLBCL cases by substitution mutations affecting Y641. As a consequence, EZH2 levels remain high, promoting a hyperproliferative state but not overt B-cell transformation. In vitro treatment of non-lymphoid somatic cells with Ruxolitinib similarly increases EZH2 levels, suggesting that there is likely to be no benefit to treating DLBCL patients with JAK inhibitors.
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